Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 81
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | ||
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | ||
| NCT02857998 | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | ||
| NCT01955304 | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | ||
| NCT01773018 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | ||
| NCT02017236 | A Food Effect Phase I Study of the Volitinib in Healthy Subjects | ||
| NCT02320409 | A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT02689752 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib | ||
| NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | ||
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | ||
| NCT03627520 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers | ||
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT05535933 | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ||
| NCT02601248 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT03128164 | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | ||
| NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | ||
| NCT02631642 | A Study of HMPL-689 in Healthy Volunteers | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | ||
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | ||
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | ||
| NCT04372407 | A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | ||
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | ||
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | ||
| NCT02133157 | Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT02601274 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | ||
| NCT02105129 | A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 | ||
| NCT03597971 | HMPL004-6599 Phase I Dose-escalating Study | ||
| NCT04755088 | Surufatinib Renal Impairment Study | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | ||
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | ||
| NCT03483259 | To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers | ||
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | ||
| NCT02374645 | A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | ||
| NCT05029635 | Phase III Study on HMPL-523 for Treatment of ITP | ||
| NCT01645215 | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | ||
| NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers |
